English
简体中文
Total: £ 56.28
Published Date: 2026-04-07 | Pages: 158 | Tables: 165 | Pharma & Healthcare
The global Angiogenesis Modulators market was valued at US$ 19800 million in 2025 and is anticipated to reach US$ 29621 million by 2032, at a CAGR of 5.9% from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Angiogenesis Modulators competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Angiogenesis Modulators are pharmaceutical or biologically active agents that regulate the formation, maturation, permeability, and regression of new blood vessels, with commercially marketed products currently dominated by inhibitory therapies. Their physical presentation varies by molecular modality and includes sterile clear solutions in single-use vials or prefilled syringes for intravitreal or intravenous administration, as well as oral tablets or capsules for systemic therapy. Structurally, the category mainly covers: biologics that bind VEGF-A, VEGF-B, PlGF, or dual pathways such as Ang-2/VEGF-A, including monoclonal antibodies and fusion proteins; small-molecule kinase inhibitors that block VEGFR1/2/3 and related signaling pathways; and a much smaller group of pro-angiogenic candidates still concentrated in development or niche clinical use. Their mechanism is to modulate endothelial-cell proliferation, migration, tube formation, vascular leakage, and vessel survival, thereby reshaping local blood supply and disease microenvironment. Current suppliers are primarily large pharmaceutical manufacturers, biosimilar developers, and specialist biopharma companies with capabilities in biologics manufacturing, sterile fill-finish, or targeted small-molecule production. Major application scenarios include oncology, neovascular retinal diseases such as wet age-related macular degeneration, diabetic macular edema, and macular edema secondary to retinal vein occlusion. In practical market terms, the commercial value of Angiogenesis Modulators is overwhelmingly concentrated in anti-angiogenic products.
Over recent years, the commercial focus of Angiogenesis Modulators has continued to shift toward segments characterized by high barriers to entry, repeated dosing, and clearer reimbursement pathways. The strongest opportunities are coming from next-generation ophthalmic anti-VEGF therapies, expansion of oncology combination regimens, and growing biosimilar penetration. In ophthalmology, faricimab, high-dose aflibercept, and multiple aflibercept and ranibizumab biosimilars are reinforcing a competitive logic centered on longer dosing intervals, improved adherence, and lower payer burden. In oncology, VEGF/VEGFR inhibitors are increasingly positioned not only as standalone anti-vascular agents but also as backbone components in combinations with immunotherapy, chemotherapy, PARP inhibitors, and locoregional treatment. At the same time, population aging is enlarging the patient pool for wet AMD, DME, and RVO-related disease, while rising cancer prevalence and longer treatment duration continue to support demand. Growth therefore comes not only from new molecules, but also from formulation upgrades, prefilled delivery systems, regional access expansion, hospital switching, and reimbursement optimization.
The challenges and restraints are equally visible. First, competition in mature angiogenesis-related indications is already intense, with originator products facing pressure from both biosimilars and same-class competitors, leading to sustained pricing and tender pressure. Second, the benefit of anti-angiogenic therapy remains highly indication-specific and dependent on line of therapy and combination design, while long-term use is constrained by resistance, variable efficacy, and safety management issues such as hypertension, bleeding, proteinuria, thrombosis, impaired wound healing, and intraocular inflammation. Third, even in large ophthalmology markets, conversion dynamics depend heavily on specialist prescribing behavior, injection burden, real-world tolerability, and reimbursement policy; in oncology, usage is strongly shaped by guideline position, evidence quality in combination regimens, and payer negotiations. Fourth, the pro-angiogenic side still has limited commercial conversion, meaning that although the topic name covers all “modulators,” large-scale recurring revenue remains overwhelmingly concentrated in the inhibitory side.
Downstream demand is moving in three clear directions. The first is a shift from simple efficacy toward durability, lower injection frequency, and better fit with outpatient workflow, which is accelerating the move from conventional monoclonal antibodies toward bispecific antibodies, high-dose fusion proteins, and longer-acting delivery approaches in ophthalmology. The second is a transition from single-pathway targeting to use as a mechanistic module within combination therapy, especially in liver cancer, colorectal cancer, renal cell carcinoma, and lung cancer, where anti-VEGF/VEGFR therapies increasingly function as foundational partners in broader regimens. The third is a move from originator-dominated markets to multi-supplier systems. As biosimilars enter, hospitals and payers become more sensitive to access, budget control, sterile manufacturing quality, cold-chain reliability, and real-world evidence. Future growth will therefore not be driven by volume alone, but by a reallocation of share according to durability, affordability, supply reliability, and evidence strength.
This report delivers a comprehensive overview of the global Angiogenesis Modulators market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Angiogenesis Modulators. The Angiogenesis Modulators market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Angiogenesis Modulators market comprehensively. Regional market sizes by Type, by Application, by Mechanism Direction, and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Angiogenesis Modulators manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Roche
Regeneron
Bayer
Novartis
Eli Lilly
Pfizer
Eisai
Exelixis
Takeda
HUTCHMED
Amgen
Sandoz
Biocon Biologics
Celltrion
Samsung Bioepis
Biogen
Dr. Reddy’s Laboratories
Hetero
Intas Pharmaceuticals
AVEO Oncology
Innovent Biologics
Shanghai Henlius
Qilu Pharmaceutical
Jiangsu Hengrui Pharmaceuticals
Boan Biotech
Chengdu Kanghong Pharmaceutical Group
Genentech
Samsung Bioepis / Biogen
Sandoz / CIMERLI current business
Dr. Reddy’s / Versavo
Biocon / KRABEVA
Segment by Type
Angiogenesis Inhibitors
Angiogenesis Stimulators
Angiogenin
Others
Segment by Mechanism Direction
Anti-angiogenic Modulators
Pro-angiogenic Modulators
Bidirectional or Context-dependent Modulators
Others
Segment by Target Breadth
Single-target Modulators
Dual-target Modulators
Multi-target Modulators
Others
by Application
Breast Cancer
Colorectal Cancer
Lung Cancer
Prostate Cancer
Others
Consumption by Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Mechanism Direction, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Angiogenesis Modulators manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Angiogenesis Modulators sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Angiogenesis Modulators Market Overview
1.1 Product Definition
1.2 Angiogenesis Modulators by Type
1.2.1 Global Angiogenesis Modulators Market Value by Type: 2025 vs 2032
1.2.2 Angiogenesis Inhibitors
1.2.3 Angiogenesis Stimulators
1.2.4 Angiogenin
1.2.5 Others
1.3 Angiogenesis Modulators by Mechanism Direction
1.3.1 Global Angiogenesis Modulators Market Value by Mechanism Direction: 2025 vs 2032
1.3.2 Anti-angiogenic Modulators
1.3.3 Pro-angiogenic Modulators
1.3.4 Bidirectional or Context-dependent Modulators
1.3.5 Others
1.4 Angiogenesis Modulators by Target Breadth
1.4.1 Global Angiogenesis Modulators Market Value by Target Breadth: 2025 vs 2032
1.4.2 Single-target Modulators
1.4.3 Dual-target Modulators
1.4.4 Multi-target Modulators
1.4.5 Others
1.5 Angiogenesis Modulators by Application
1.5.1 Global Angiogenesis Modulators Market Value by Application: 2025 vs 2032
1.5.2 Breast Cancer
1.5.3 Colorectal Cancer
1.5.4 Lung Cancer
1.5.5 Prostate Cancer
1.5.6 Others
1.6 Global Angiogenesis Modulators Market Size Estimates and Forecasts
1.6.1 Global Angiogenesis Modulators Revenue 2021–2032
1.6.2 Global Angiogenesis Modulators Sales 2021–2032
1.6.3 Global Angiogenesis Modulators Market Average Price (2021–2032)
1.7 Assumptions and Limitations
2 Angiogenesis Modulators Market Competition by Manufacturers
2.1 Global Angiogenesis Modulators Sales Market Share by Manufacturers (2021–2026)
2.2 Global Angiogenesis Modulators Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Angiogenesis Modulators Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Angiogenesis Modulators, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Angiogenesis Modulators, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Angiogenesis Modulators, Product Types and Applications
2.7 Global Key Manufacturers of Angiogenesis Modulators, Date of Entry into the Industry
2.8 Global Angiogenesis Modulators Market Competitive Situation and Trends
2.8.1 Global Angiogenesis Modulators Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Angiogenesis Modulators Players Market Share by Revenue
2.8.3 Global Angiogenesis Modulators Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Angiogenesis Modulators Market Scenario by Region
3.1 Global Angiogenesis Modulators Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Angiogenesis Modulators Sales by Region: 2021–2032
3.2.1 Global Angiogenesis Modulators Sales by Region: 2021–2026
3.2.2 Global Angiogenesis Modulators Sales by Region: 2027–2032
3.3 Global Angiogenesis Modulators Revenue by Region: 2021–2032
3.3.1 Global Angiogenesis Modulators Revenue by Region: 2021–2026
3.3.2 Global Angiogenesis Modulators Revenue by Region: 2027–2032
3.4 North America Angiogenesis Modulators Market Facts & Figures by Country
3.4.1 North America Angiogenesis Modulators Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Angiogenesis Modulators Sales by Country (2021–2032)
3.4.3 North America Angiogenesis Modulators Revenue by Country (2021–2032)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Angiogenesis Modulators Market Facts & Figures by Country
3.5.1 Europe Angiogenesis Modulators Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Angiogenesis Modulators Sales by Country (2021–2032)
3.5.3 Europe Angiogenesis Modulators Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Angiogenesis Modulators Market Facts & Figures by Region
3.6.1 Asia Pacific Angiogenesis Modulators Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Angiogenesis Modulators Sales by Region (2021–2032)
3.6.3 Asia Pacific Angiogenesis Modulators Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Angiogenesis Modulators Market Facts & Figures by Country
3.7.1 Latin America Angiogenesis Modulators Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Angiogenesis Modulators Sales by Country (2021–2032)
3.7.3 Latin America Angiogenesis Modulators Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Angiogenesis Modulators Market Facts & Figures by Country
3.8.1 Middle East and Africa Angiogenesis Modulators Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Angiogenesis Modulators Sales by Country (2021–2032)
3.8.3 Middle East and Africa Angiogenesis Modulators Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Angiogenesis Modulators Sales by Type (2021–2032)
4.1.1 Global Angiogenesis Modulators Sales by Type (2021–2026)
4.1.2 Global Angiogenesis Modulators Sales by Type (2027–2032)
4.1.3 Global Angiogenesis Modulators Sales Market Share by Type (2021–2032)
4.2 Global Angiogenesis Modulators Revenue by Type (2021–2032)
4.2.1 Global Angiogenesis Modulators Revenue by Type (2021–2026)
4.2.2 Global Angiogenesis Modulators Revenue by Type (2027–2032)
4.2.3 Global Angiogenesis Modulators Revenue Market Share by Type (2021–2032)
4.3 Global Angiogenesis Modulators Price by Type (2021–2032)
5 Segment by Application
5.1 Global Angiogenesis Modulators Sales by Application (2021–2032)
5.1.1 Global Angiogenesis Modulators Sales by Application (2021–2026)
5.1.2 Global Angiogenesis Modulators Sales by Application (2027–2032)
5.1.3 Global Angiogenesis Modulators Sales Market Share by Application (2021–2032)
5.2 Global Angiogenesis Modulators Revenue by Application (2021–2032)
5.2.1 Global Angiogenesis Modulators Revenue by Application (2021–2026)
5.2.2 Global Angiogenesis Modulators Revenue by Application (2027–2032)
5.2.3 Global Angiogenesis Modulators Revenue Market Share by Application (2021–2032)
5.3 Global Angiogenesis Modulators Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Roche
6.1.1 Roche Company Information
6.1.2 Roche Description and Business Overview
6.1.3 Roche Angiogenesis Modulators Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Roche Angiogenesis Modulators Product Portfolio
6.1.5 Roche Recent Developments/Updates
6.2 Regeneron
6.2.1 Regeneron Company Information
6.2.2 Regeneron Description and Business Overview
6.2.3 Regeneron Angiogenesis Modulators Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Regeneron Angiogenesis Modulators Product Portfolio
6.2.5 Regeneron Recent Developments/Updates
6.3 Bayer
6.3.1 Bayer Company Information
6.3.2 Bayer Description and Business Overview
6.3.3 Bayer Angiogenesis Modulators Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Bayer Angiogenesis Modulators Product Portfolio
6.3.5 Bayer Recent Developments/Updates
6.4 Novartis
6.4.1 Novartis Company Information
6.4.2 Novartis Description and Business Overview
6.4.3 Novartis Angiogenesis Modulators Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Novartis Angiogenesis Modulators Product Portfolio
6.4.5 Novartis Recent Developments/Updates
6.5 Eli Lilly
6.5.1 Eli Lilly Company Information
6.5.2 Eli Lilly Description and Business Overview
6.5.3 Eli Lilly Angiogenesis Modulators Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Eli Lilly Angiogenesis Modulators Product Portfolio
6.5.5 Eli Lilly Recent Developments/Updates
6.6 Pfizer
6.6.1 Pfizer Company Information
6.6.2 Pfizer Description and Business Overview
6.6.3 Pfizer Angiogenesis Modulators Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Pfizer Angiogenesis Modulators Product Portfolio
6.6.5 Pfizer Recent Developments/Updates
6.7 Eisai
6.7.1 Eisai Company Information
6.7.2 Eisai Description and Business Overview
6.7.3 Eisai Angiogenesis Modulators Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Eisai Angiogenesis Modulators Product Portfolio
6.7.5 Eisai Recent Developments/Updates
6.8 Exelixis
6.8.1 Exelixis Company Information
6.8.2 Exelixis Description and Business Overview
6.8.3 Exelixis Angiogenesis Modulators Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Exelixis Angiogenesis Modulators Product Portfolio
6.8.5 Exelixis Recent Developments/Updates
6.9 Takeda
6.9.1 Takeda Company Information
6.9.2 Takeda Description and Business Overview
6.9.3 Takeda Angiogenesis Modulators Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Takeda Angiogenesis Modulators Product Portfolio
6.9.5 Takeda Recent Developments/Updates
6.10 HUTCHMED
6.10.1 HUTCHMED Company Information
6.10.2 HUTCHMED Description and Business Overview
6.10.3 HUTCHMED Angiogenesis Modulators Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 HUTCHMED Angiogenesis Modulators Product Portfolio
6.10.5 HUTCHMED Recent Developments/Updates
6.11 Amgen
6.11.1 Amgen Company Information
6.11.2 Amgen Description and Business Overview
6.11.3 Amgen Angiogenesis Modulators Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Amgen Angiogenesis Modulators Product Portfolio
6.11.5 Amgen Recent Developments/Updates
6.12 Sandoz
6.12.1 Sandoz Company Information
6.12.2 Sandoz Description and Business Overview
6.12.3 Sandoz Angiogenesis Modulators Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Sandoz Angiogenesis Modulators Product Portfolio
6.12.5 Sandoz Recent Developments/Updates
6.13 Biocon Biologics
6.13.1 Biocon Biologics Company Information
6.13.2 Biocon Biologics Description and Business Overview
6.13.3 Biocon Biologics Angiogenesis Modulators Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Biocon Biologics Angiogenesis Modulators Product Portfolio
6.13.5 Biocon Biologics Recent Developments/Updates
6.14 Celltrion
6.14.1 Celltrion Company Information
6.14.2 Celltrion Description and Business Overview
6.14.3 Celltrion Angiogenesis Modulators Sales, Revenue, and Gross Margin (2021–2026)
6.14.4 Celltrion Angiogenesis Modulators Product Portfolio
6.14.5 Celltrion Recent Developments/Updates
6.15 Samsung Bioepis
6.15.1 Samsung Bioepis Company Information
6.15.2 Samsung Bioepis Description and Business Overview
6.15.3 Samsung Bioepis Angiogenesis Modulators Sales, Revenue, and Gross Margin (2021–2026)
6.15.4 Samsung Bioepis Angiogenesis Modulators Product Portfolio
6.15.5 Samsung Bioepis Recent Developments/Updates
6.16 Biogen
6.16.1 Biogen Company Information
6.16.2 Biogen Description and Business Overview
6.16.3 Biogen Angiogenesis Modulators Sales, Revenue, and Gross Margin (2021–2026)
6.16.4 Biogen Angiogenesis Modulators Product Portfolio
6.16.5 Biogen Recent Developments/Updates
6.17 Dr. Reddy’s Laboratories
6.17.1 Dr. Reddy’s Laboratories Company Information
6.17.2 Dr. Reddy’s Laboratories Description and Business Overview
6.17.3 Dr. Reddy’s Laboratories Angiogenesis Modulators Sales, Revenue, and Gross Margin (2021–2026)
6.17.4 Dr. Reddy’s Laboratories Angiogenesis Modulators Product Portfolio
6.17.5 Dr. Reddy’s Laboratories Recent Developments/Updates
6.18 Hetero
6.18.1 Hetero Company Information
6.18.2 Hetero Description and Business Overview
6.18.3 Hetero Angiogenesis Modulators Sales, Revenue, and Gross Margin (2021–2026)
6.18.4 Hetero Angiogenesis Modulators Product Portfolio
6.18.5 Hetero Recent Developments/Updates
6.19 Intas Pharmaceuticals
6.19.1 Intas Pharmaceuticals Company Information
6.19.2 Intas Pharmaceuticals Description and Business Overview
6.19.3 Intas Pharmaceuticals Angiogenesis Modulators Sales, Revenue, and Gross Margin (2021–2026)
6.19.4 Intas Pharmaceuticals Angiogenesis Modulators Product Portfolio
6.19.5 Intas Pharmaceuticals Recent Developments/Updates
6.20 AVEO Oncology
6.20.1 AVEO Oncology Company Information
6.20.2 AVEO Oncology Description and Business Overview
6.20.3 AVEO Oncology Angiogenesis Modulators Sales, Revenue, and Gross Margin (2021–2026)
6.20.4 AVEO Oncology Angiogenesis Modulators Product Portfolio
6.20.5 AVEO Oncology Recent Developments/Updates
6.21 Innovent Biologics
6.21.1 Innovent Biologics Company Information
6.21.2 Innovent Biologics Description and Business Overview
6.21.3 Innovent Biologics Angiogenesis Modulators Sales, Revenue, and Gross Margin (2021–2026)
6.21.4 Innovent Biologics Angiogenesis Modulators Product Portfolio
6.21.5 Innovent Biologics Recent Developments/Updates
6.22 Shanghai Henlius
6.22.1 Shanghai Henlius Company Information
6.22.2 Shanghai Henlius Description and Business Overview
6.22.3 Shanghai Henlius Angiogenesis Modulators Sales, Revenue, and Gross Margin (2021–2026)
6.22.4 Shanghai Henlius Angiogenesis Modulators Product Portfolio
6.22.5 Shanghai Henlius Recent Developments/Updates
6.23 Qilu Pharmaceutical
6.23.1 Qilu Pharmaceutical Company Information
6.23.2 Qilu Pharmaceutical Description and Business Overview
6.23.3 Qilu Pharmaceutical Angiogenesis Modulators Sales, Revenue, and Gross Margin (2021–2026)
6.23.4 Qilu Pharmaceutical Angiogenesis Modulators Product Portfolio
6.23.5 Qilu Pharmaceutical Recent Developments/Updates
6.24 Jiangsu Hengrui Pharmaceuticals
6.24.1 Jiangsu Hengrui Pharmaceuticals Company Information
6.24.2 Jiangsu Hengrui Pharmaceuticals Description and Business Overview
6.24.3 Jiangsu Hengrui Pharmaceuticals Angiogenesis Modulators Sales, Revenue, and Gross Margin (2021–2026)
6.24.4 Jiangsu Hengrui Pharmaceuticals Angiogenesis Modulators Product Portfolio
6.24.5 Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
6.25 Boan Biotech
6.25.1 Boan Biotech Company Information
6.25.2 Boan Biotech Description and Business Overview
6.25.3 Boan Biotech Angiogenesis Modulators Sales, Revenue, and Gross Margin (2021–2026)
6.25.4 Boan Biotech Angiogenesis Modulators Product Portfolio
6.25.5 Boan Biotech Recent Developments/Updates
6.26 Chengdu Kanghong Pharmaceutical Group
6.26.1 Chengdu Kanghong Pharmaceutical Group Company Information
6.26.2 Chengdu Kanghong Pharmaceutical Group Description and Business Overview
6.26.3 Chengdu Kanghong Pharmaceutical Group Angiogenesis Modulators Sales, Revenue, and Gross Margin (2021–2026)
6.26.4 Chengdu Kanghong Pharmaceutical Group Angiogenesis Modulators Product Portfolio
6.26.5 Chengdu Kanghong Pharmaceutical Group Recent Developments/Updates
6.27 Genentech
6.27.1 Genentech Company Information
6.27.2 Genentech Description and Business Overview
6.27.3 Genentech Angiogenesis Modulators Sales, Revenue, and Gross Margin (2021–2026)
6.27.4 Genentech Angiogenesis Modulators Product Portfolio
6.27.5 Genentech Recent Developments/Updates
6.28 Samsung Bioepis / Biogen
6.28.1 Samsung Bioepis / Biogen Company Information
6.28.2 Samsung Bioepis / Biogen Description and Business Overview
6.28.3 Samsung Bioepis / Biogen Angiogenesis Modulators Sales, Revenue, and Gross Margin (2021–2026)
6.28.4 Samsung Bioepis / Biogen Angiogenesis Modulators Product Portfolio
6.28.5 Samsung Bioepis / Biogen Recent Developments/Updates
6.29 Sandoz / CIMERLI current business
6.29.1 Sandoz / CIMERLI current business Company Information
6.29.2 Sandoz / CIMERLI current business Description and Business Overview
6.29.3 Sandoz / CIMERLI current business Angiogenesis Modulators Sales, Revenue, and Gross Margin (2021–2026)
6.29.4 Sandoz / CIMERLI current business Angiogenesis Modulators Product Portfolio
6.29.5 Sandoz / CIMERLI current business Recent Developments/Updates
6.30 Dr. Reddy’s / Versavo
6.30.1 Dr. Reddy’s / Versavo Company Information
6.30.2 Dr. Reddy’s / Versavo Description and Business Overview
6.30.3 Dr. Reddy’s / Versavo Angiogenesis Modulators Sales, Revenue, and Gross Margin (2021–2026)
6.30.4 Dr. Reddy’s / Versavo Angiogenesis Modulators Product Portfolio
6.30.5 Dr. Reddy’s / Versavo Recent Developments/Updates
6.31 Biocon / KRABEVA
6.31.1 Biocon / KRABEVA Company Information
6.31.2 Biocon / KRABEVA Description and Business Overview
6.31.3 Biocon / KRABEVA Angiogenesis Modulators Sales, Revenue, and Gross Margin (2021–2026)
6.31.4 Biocon / KRABEVA Angiogenesis Modulators Product Portfolio
6.31.5 Biocon / KRABEVA Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Angiogenesis Modulators Industry Chain Analysis
7.2 Angiogenesis Modulators Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Angiogenesis Modulators Production Mode & Process Analysis
7.4 Angiogenesis Modulators Sales and Marketing
7.4.1 Angiogenesis Modulators Sales Channels
7.4.2 Angiogenesis Modulators Distributors
7.5 Angiogenesis Modulators Customer Analysis
8 Angiogenesis Modulators Market Dynamics
8.1 Angiogenesis Modulators Industry Trends
8.2 Angiogenesis Modulators Market Drivers
8.3 Angiogenesis Modulators Market Challenges
8.4 Angiogenesis Modulators Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Angiogenesis Modulators Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Angiogenesis Modulators Market Value by Mechanism Direction (US$ Million), 2025 vs 2032
Table 3. Global Angiogenesis Modulators Market Value by Target Breadth (US$ Million), 2025 vs 2032
Table 4. Global Angiogenesis Modulators Market Value by Application (US$ Million), 2025 vs 2032
Table 5. Global Angiogenesis Modulators Market Competitive Situation by Manufacturers in 2025
Table 6. Global Angiogenesis Modulators Sales (K Units) of Key Manufacturers (2021–2026)
Table 7. Global Angiogenesis Modulators Sales Market Share by Manufacturers (2021–2026)
Table 8. Global Angiogenesis Modulators Revenue (US$ Million) by Manufacturers (2021–2026)
Table 9. Global Angiogenesis Modulators Revenue Share by Manufacturers (2021–2026)
Table 10. Global Market Angiogenesis Modulators Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 11. Global Key Players of Angiogenesis Modulators, Industry Ranking, 2023 vs 2024 vs 2025
Table 12. Global Key Manufacturers of Angiogenesis Modulators, Manufacturing Sites and Headquarters
Table 13. Global Key Manufacturers of Angiogenesis Modulators, Product Types and Applications
Table 14. Global Key Manufacturers of Angiogenesis Modulators, Date of Entry into the Industry
Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 16. Global Angiogenesis Modulators Companies by Tier (Tier 1, Tier 2, Tier 3), based on Angiogenesis Modulators Revenue, 2025
Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 18. Global Angiogenesis Modulators Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 19. Global Angiogenesis Modulators Sales by Region (K Units), 2021–2026
Table 20. Global Angiogenesis Modulators Sales Market Share by Region (2021–2026)
Table 21. Global Angiogenesis Modulators Sales by Region (K Units), 2027–2032
Table 22. Global Angiogenesis Modulators Sales Market Share by Region (2027–2032)
Table 23. Global Angiogenesis Modulators Revenue by Region (US$ Million), 2021–2026
Table 24. Global Angiogenesis Modulators Revenue Market Share by Region (2021–2026)
Table 25. Global Angiogenesis Modulators Revenue by Region (US$ Million), 2027–2032
Table 26. Global Angiogenesis Modulators Revenue Market Share by Region (2027–2032)
Table 27. North America Angiogenesis Modulators Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 28. North America Angiogenesis Modulators Sales by Country (K Units), 2021–2026
Table 29. North America Angiogenesis Modulators Sales by Country (K Units), 2027–2032
Table 30. North America Angiogenesis Modulators Revenue by Country (US$ Million), 2021–2026
Table 31. North America Angiogenesis Modulators Revenue by Country (US$ Million), 2027–2032
Table 32. Europe Angiogenesis Modulators Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 33. Europe Angiogenesis Modulators Sales by Country (K Units), 2021–2026
Table 34. Europe Angiogenesis Modulators Sales by Country (K Units), 2027–2032
Table 35. Europe Angiogenesis Modulators Revenue by Country (US$ Million), 2021–2026
Table 36. Europe Angiogenesis Modulators Revenue by Country (US$ Million), 2027–2032
Table 37. Asia Pacific Angiogenesis Modulators Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 38. Asia Pacific Angiogenesis Modulators Sales by Region (K Units), 2021–2026
Table 39. Asia Pacific Angiogenesis Modulators Sales by Region (K Units), 2027–2032
Table 40. Asia Pacific Angiogenesis Modulators Revenue by Region (US$ Million), 2021–2026
Table 41. Asia Pacific Angiogenesis Modulators Revenue by Region (US$ Million), 2027–2032
Table 42. Latin America Angiogenesis Modulators Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 43. Latin America Angiogenesis Modulators Sales by Country (K Units), 2021–2026
Table 44. Latin America Angiogenesis Modulators Sales by Country (K Units), 2027–2032
Table 45. Latin America Angiogenesis Modulators Revenue by Country (US$ Million), 2021–2026
Table 46. Latin America Angiogenesis Modulators Revenue by Country (US$ Million), 2027–2032
Table 47. Middle East and Africa Angiogenesis Modulators Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 48. Middle East and Africa Angiogenesis Modulators Sales by Country (K Units), 2021–2026
Table 49. Middle East and Africa Angiogenesis Modulators Sales by Country (K Units), 2027–2032
Table 50. Middle East and Africa Angiogenesis Modulators Revenue by Country (US$ Million), 2021–2026
Table 51. Middle East and Africa Angiogenesis Modulators Revenue by Country (US$ Million), 2027–2032
Table 52. Global Angiogenesis Modulators Sales (K Units) by Type (2021–2026)
Table 53. Global Angiogenesis Modulators Sales (K Units) by Type (2027–2032)
Table 54. Global Angiogenesis Modulators Sales Market Share by Type (2021–2026)
Table 55. Global Angiogenesis Modulators Sales Market Share by Type (2027–2032)
Table 56. Global Angiogenesis Modulators Revenue (US$ Million) by Type (2021–2026)
Table 57. Global Angiogenesis Modulators Revenue (US$ Million) by Type (2027–2032)
Table 58. Global Angiogenesis Modulators Revenue Market Share by Type (2021–2026)
Table 59. Global Angiogenesis Modulators Revenue Market Share by Type (2027–2032)
Table 60. Global Angiogenesis Modulators Price (US$/Unit) by Type (2021–2026)
Table 61. Global Angiogenesis Modulators Price (US$/Unit) by Type (2027–2032)
Table 62. Global Angiogenesis Modulators Sales (K Units) by Application (2021–2026)
Table 63. Global Angiogenesis Modulators Sales (K Units) by Application (2027–2032)
Table 64. Global Angiogenesis Modulators Sales Market Share by Application (2021–2026)
Table 65. Global Angiogenesis Modulators Sales Market Share by Application (2027–2032)
Table 66. Global Angiogenesis Modulators Revenue (US$ Million) by Application (2021–2026)
Table 67. Global Angiogenesis Modulators Revenue (US$ Million) by Application (2027–2032)
Table 68. Global Angiogenesis Modulators Revenue Market Share by Application (2021–2026)
Table 69. Global Angiogenesis Modulators Revenue Market Share by Application (2027–2032)
Table 70. Global Angiogenesis Modulators Price (US$/Unit) by Application (2021–2026)
Table 71. Global Angiogenesis Modulators Price (US$/Unit) by Application (2027–2032)
Table 72. Roche Company Information
Table 73. Roche Description and Business Overview
Table 74. Roche Angiogenesis Modulators Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 75. Roche Angiogenesis Modulators Product
Table 76. Roche Recent Developments/Updates
Table 77. Regeneron Company Information
Table 78. Regeneron Description and Business Overview
Table 79. Regeneron Angiogenesis Modulators Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 80. Regeneron Angiogenesis Modulators Product
Table 81. Regeneron Recent Developments/Updates
Table 82. Bayer Company Information
Table 83. Bayer Description and Business Overview
Table 84. Bayer Angiogenesis Modulators Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 85. Bayer Angiogenesis Modulators Product
Table 86. Bayer Recent Developments/Updates
Table 87. Novartis Company Information
Table 88. Novartis Description and Business Overview
Table 89. Novartis Angiogenesis Modulators Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 90. Novartis Angiogenesis Modulators Product
Table 91. Novartis Recent Developments/Updates
Table 92. Eli Lilly Company Information
Table 93. Eli Lilly Description and Business Overview
Table 94. Eli Lilly Angiogenesis Modulators Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 95. Eli Lilly Angiogenesis Modulators Product
Table 96. Eli Lilly Recent Developments/Updates
Table 97. Pfizer Company Information
Table 98. Pfizer Description and Business Overview
Table 99. Pfizer Angiogenesis Modulators Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 100. Pfizer Angiogenesis Modulators Product
Table 101. Pfizer Recent Developments/Updates
Table 102. Eisai Company Information
Table 103. Eisai Description and Business Overview
Table 104. Eisai Angiogenesis Modulators Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 105. Eisai Angiogenesis Modulators Product
Table 106. Eisai Recent Developments/Updates
Table 107. Exelixis Company Information
Table 108. Exelixis Description and Business Overview
Table 109. Exelixis Angiogenesis Modulators Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 110. Exelixis Angiogenesis Modulators Product
Table 111. Exelixis Recent Developments/Updates
Table 112. Takeda Company Information
Table 113. Takeda Description and Business Overview
Table 114. Takeda Angiogenesis Modulators Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 115. Takeda Angiogenesis Modulators Product
Table 116. Takeda Recent Developments/Updates
Table 117. HUTCHMED Company Information
Table 118. HUTCHMED Description and Business Overview
Table 119. HUTCHMED Angiogenesis Modulators Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 120. HUTCHMED Angiogenesis Modulators Product
Table 121. HUTCHMED Recent Developments/Updates
Table 122. Amgen Company Information
Table 123. Amgen Description and Business Overview
Table 124. Amgen Angiogenesis Modulators Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 125. Amgen Angiogenesis Modulators Product
Table 126. Amgen Recent Developments/Updates
Table 127. Sandoz Company Information
Table 128. Sandoz Description and Business Overview
Table 129. Sandoz Angiogenesis Modulators Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 130. Sandoz Angiogenesis Modulators Product
Table 131. Sandoz Recent Developments/Updates
Table 132. Biocon Biologics Company Information
Table 133. Biocon Biologics Description and Business Overview
Table 134. Biocon Biologics Angiogenesis Modulators Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 135. Biocon Biologics Angiogenesis Modulators Product
Table 136. Biocon Biologics Recent Developments/Updates
Table 137. Celltrion Company Information
Table 138. Celltrion Description and Business Overview
Table 139. Celltrion Angiogenesis Modulators Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 140. Celltrion Angiogenesis Modulators Product
Table 141. Celltrion Recent Developments/Updates
Table 142. Samsung Bioepis Company Information
Table 143. Samsung Bioepis Description and Business Overview
Table 144. Samsung Bioepis Angiogenesis Modulators Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 145. Samsung Bioepis Angiogenesis Modulators Product
Table 146. Samsung Bioepis Recent Developments/Updates
Table 147. Biogen Company Information
Table 148. Biogen Description and Business Overview
Table 149. Biogen Angiogenesis Modulators Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 150. Biogen Angiogenesis Modulators Product
Table 151. Biogen Recent Developments/Updates
Table 152. Dr. Reddy’s Laboratories Company Information
Table 153. Dr. Reddy’s Laboratories Description and Business Overview
Table 154. Dr. Reddy’s Laboratories Angiogenesis Modulators Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 155. Dr. Reddy’s Laboratories Angiogenesis Modulators Product
Table 156. Dr. Reddy’s Laboratories Recent Developments/Updates
Table 157. Hetero Company Information
Table 158. Hetero Description and Business Overview
Table 159. Hetero Angiogenesis Modulators Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 160. Hetero Angiogenesis Modulators Product
Table 161. Hetero Recent Developments/Updates
Table 162. Intas Pharmaceuticals Company Information
Table 163. Intas Pharmaceuticals Description and Business Overview
Table 164. Intas Pharmaceuticals Angiogenesis Modulators Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 165. Intas Pharmaceuticals Angiogenesis Modulators Product
Table 166. Intas Pharmaceuticals Recent Developments/Updates
Table 167. AVEO Oncology Company Information
Table 168. AVEO Oncology Description and Business Overview
Table 169. AVEO Oncology Angiogenesis Modulators Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 170. AVEO Oncology Angiogenesis Modulators Product
Table 171. AVEO Oncology Recent Developments/Updates
Table 172. Innovent Biologics Company Information
Table 173. Innovent Biologics Description and Business Overview
Table 174. Innovent Biologics Angiogenesis Modulators Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 175. Innovent Biologics Angiogenesis Modulators Product
Table 176. Innovent Biologics Recent Developments/Updates
Table 177. Shanghai Henlius Company Information
Table 178. Shanghai Henlius Description and Business Overview
Table 179. Shanghai Henlius Angiogenesis Modulators Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 180. Shanghai Henlius Angiogenesis Modulators Product
Table 181. Shanghai Henlius Recent Developments/Updates
Table 182. Qilu Pharmaceutical Company Information
Table 183. Qilu Pharmaceutical Description and Business Overview
Table 184. Qilu Pharmaceutical Angiogenesis Modulators Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 185. Qilu Pharmaceutical Angiogenesis Modulators Product
Table 186. Qilu Pharmaceutical Recent Developments/Updates
Table 187. Jiangsu Hengrui Pharmaceuticals Company Information
Table 188. Jiangsu Hengrui Pharmaceuticals Description and Business Overview
Table 189. Jiangsu Hengrui Pharmaceuticals Angiogenesis Modulators Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 190. Jiangsu Hengrui Pharmaceuticals Angiogenesis Modulators Product
Table 191. Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
Table 192. Boan Biotech Company Information
Table 193. Boan Biotech Description and Business Overview
Table 194. Boan Biotech Angiogenesis Modulators Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 195. Boan Biotech Angiogenesis Modulators Product
Table 196. Boan Biotech Recent Developments/Updates
Table 197. Chengdu Kanghong Pharmaceutical Group Company Information
Table 198. Chengdu Kanghong Pharmaceutical Group Description and Business Overview
Table 199. Chengdu Kanghong Pharmaceutical Group Angiogenesis Modulators Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 200. Chengdu Kanghong Pharmaceutical Group Angiogenesis Modulators Product
Table 201. Chengdu Kanghong Pharmaceutical Group Recent Developments/Updates
Table 202. Genentech Company Information
Table 203. Genentech Description and Business Overview
Table 204. Genentech Angiogenesis Modulators Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 205. Genentech Angiogenesis Modulators Product
Table 206. Genentech Recent Developments/Updates
Table 207. Samsung Bioepis / Biogen Company Information
Table 208. Samsung Bioepis / Biogen Description and Business Overview
Table 209. Samsung Bioepis / Biogen Angiogenesis Modulators Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 210. Samsung Bioepis / Biogen Angiogenesis Modulators Product
Table 211. Samsung Bioepis / Biogen Recent Developments/Updates
Table 212. Sandoz / CIMERLI current business Company Information
Table 213. Sandoz / CIMERLI current business Description and Business Overview
Table 214. Sandoz / CIMERLI current business Angiogenesis Modulators Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 215. Sandoz / CIMERLI current business Angiogenesis Modulators Product
Table 216. Sandoz / CIMERLI current business Recent Developments/Updates
Table 217. Dr. Reddy’s / Versavo Company Information
Table 218. Dr. Reddy’s / Versavo Description and Business Overview
Table 219. Dr. Reddy’s / Versavo Angiogenesis Modulators Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 220. Dr. Reddy’s / Versavo Angiogenesis Modulators Product
Table 221. Dr. Reddy’s / Versavo Recent Developments/Updates
Table 222. Biocon / KRABEVA Company Information
Table 223. Biocon / KRABEVA Description and Business Overview
Table 224. Biocon / KRABEVA Angiogenesis Modulators Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 225. Biocon / KRABEVA Angiogenesis Modulators Product
Table 226. Biocon / KRABEVA Recent Developments/Updates
Table 227. Key Raw Materials Lists
Table 228. Raw Materials Key Suppliers Lists
Table 229. Angiogenesis Modulators Distributors List
Table 230. Angiogenesis Modulators Customers List
Table 231. Angiogenesis Modulators Market Trends
Table 232. Angiogenesis Modulators Market Drivers
Table 233. Angiogenesis Modulators Market Challenges
Table 234. Angiogenesis Modulators Market Restraints
Table 235. Research Programs/Design for This Report
Table 236. Key Data Information from Secondary Sources
Table 237. Key Data Information from Primary Sources
Table 238. Authors List of This Report
List of Figures
Figure 1. Product Picture of Angiogenesis Modulators
Figure 2. Global Angiogenesis Modulators Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Angiogenesis Modulators Market Share by Type: 2025 & 2032
Figure 4. Angiogenesis Inhibitors Product Picture
Figure 5. Angiogenesis Stimulators Product Picture
Figure 6. Angiogenin Product Picture
Figure 7. Others Product Picture
Figure 8. Global Angiogenesis Modulators Market Value by Mechanism Direction (US$ Million), 2021–2032
Figure 9. Global Angiogenesis Modulators Market Share by Mechanism Direction: 2025 vs 2032
Figure 10. Anti-angiogenic Modulators Product Picture
Figure 11. Pro-angiogenic Modulators Product Picture
Figure 12. Bidirectional or Context-dependent Modulators Product Picture
Figure 13. Others Product Picture
Figure 14. Global Angiogenesis Modulators Market Value by Target Breadth (US$ Million), 2021–2032
Figure 15. Global Angiogenesis Modulators Market Share by Target Breadth: 2025 vs 2032
Figure 16. Single-target Modulators Product Picture
Figure 17. Dual-target Modulators Product Picture
Figure 18. Multi-target Modulators Product Picture
Figure 19. Others Product Picture
Figure 20. Global Angiogenesis Modulators Market Value by Application (US$ Million), 2021–2032
Figure 21. Global Angiogenesis Modulators Market Share by Application: 2025 & 2032
Figure 22. Breast Cancer
Figure 23. Colorectal Cancer
Figure 24. Lung Cancer
Figure 25. Prostate Cancer
Figure 26. Others
Figure 27. Global Angiogenesis Modulators Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 28. Global Angiogenesis Modulators Market Size (US$ Million), 2021–2032
Figure 29. Global Angiogenesis Modulators Sales (K Units), 2021–2032
Figure 30. Global Angiogenesis Modulators Average Price (US$/Unit), 2021–2032
Figure 31. Angiogenesis Modulators Report Years Considered
Figure 32. Angiogenesis Modulators Sales Share by Manufacturers in 2025
Figure 33. Global Angiogenesis Modulators Revenue Share by Manufacturers in 2025
Figure 34. Top 5 and Top 10 Global Angiogenesis Modulators Players: Market Share by Revenue in Angiogenesis Modulators in 2025
Figure 35. Angiogenesis Modulators Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 36. Global Angiogenesis Modulators Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 37. North America Angiogenesis Modulators Sales Market Share by Country (2021–2032)
Figure 38. North America Angiogenesis Modulators Revenue Market Share by Country (2021–2032)
Figure 39. U.S. Angiogenesis Modulators Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Canada Angiogenesis Modulators Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Europe Angiogenesis Modulators Sales Market Share by Country (2021–2032)
Figure 42. Europe Angiogenesis Modulators Revenue Market Share by Country (2021–2032)
Figure 43. Germany Angiogenesis Modulators Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. France Angiogenesis Modulators Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. U.K. Angiogenesis Modulators Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Italy Angiogenesis Modulators Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Russia Angiogenesis Modulators Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Asia Pacific Angiogenesis Modulators Sales Market Share by Region (2021–2032)
Figure 49. Asia Pacific Angiogenesis Modulators Revenue Market Share by Region (2021–2032)
Figure 50. China Angiogenesis Modulators Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. Japan Angiogenesis Modulators Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. South Korea Angiogenesis Modulators Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. India Angiogenesis Modulators Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. Australia Angiogenesis Modulators Revenue Growth Rate (US$ Million), 2021–2032
Figure 55. Taiwan Angiogenesis Modulators Revenue Growth Rate (US$ Million), 2021–2032
Figure 56. Indonesia Angiogenesis Modulators Revenue Growth Rate (US$ Million), 2021–2032
Figure 57. Thailand Angiogenesis Modulators Revenue Growth Rate (US$ Million), 2021–2032
Figure 58. Malaysia Angiogenesis Modulators Revenue Growth Rate (US$ Million), 2021–2032
Figure 59. Philippines Angiogenesis Modulators Revenue Growth Rate (US$ Million), 2021–2032
Figure 60. Latin America Angiogenesis Modulators Sales Market Share by Country (2021–2032)
Figure 61. Latin America Angiogenesis Modulators Revenue Market Share by Country (2021–2032)
Figure 62. Mexico Angiogenesis Modulators Revenue Growth Rate (US$ Million), 2021–2032
Figure 63. Brazil Angiogenesis Modulators Revenue Growth Rate (US$ Million), 2021–2032
Figure 64. Argentina Angiogenesis Modulators Revenue Growth Rate (US$ Million), 2021–2032
Figure 65. Middle East and Africa Angiogenesis Modulators Sales Market Share by Country (2021–2032)
Figure 66. Middle East and Africa Angiogenesis Modulators Revenue Market Share by Country (2021–2032)
Figure 67. Turkey Angiogenesis Modulators Revenue Growth Rate (US$ Million), 2021–2032
Figure 68. Saudi Arabia Angiogenesis Modulators Revenue Growth Rate (US$ Million), 2021–2032
Figure 69. UAE Angiogenesis Modulators Revenue Growth Rate (US$ Million), 2021–2032
Figure 70. Global Sales Market Share of Angiogenesis Modulators by Type (2021–2032)
Figure 71. Global Revenue Market Share of Angiogenesis Modulators by Type (2021–2032)
Figure 72. Global Angiogenesis Modulators Price (US$/Unit) by Type (2021–2032)
Figure 73. Global Sales Market Share of Angiogenesis Modulators by Application (2021–2032)
Figure 74. Global Revenue Market Share of Angiogenesis Modulators by Application (2021–2032)
Figure 75. Global Angiogenesis Modulators Price (US$/Unit) by Application (2021–2032)
Figure 76. Angiogenesis Modulators Value Chain
Figure 77. Channels of Distribution (Direct Vs Distribution)
Figure 78. Bottom-up and Top-down Approaches for This Report
Figure 79. Data Triangulation
Figure 80. Key Executives Interviewed
